From complex chemistry to patientready medicines: The value of integrated drug substance & drug product expertise
Some molecules fit established development pathways. Others demand a deeper understanding of chemistry, formulation and analytical science to overcome challenges around bioavailability, manufacturability and performance. In these programmes, collaboration across drug substance and drug product disciplines becomes a critical advantage and can make a meaningful difference.
Almac brings together deep experience in API development and manufacture, alongside extensive drug product development, manufacture, packaging and clinical supply capabilities. Together, this creates a connected approach designed to support programmes from early development through to commercial supply, helping clients reduce complexity, improve decision-making and maintain momentum.
Strength in RSMs, intermediates & API development
A robust API strategy begins before the final drug substance. Reliable access to regulatory starting materials, advanced intermediates and well-understood synthetic routes can have a significant impact on programme resilience, scalability and cost.
The ability to develop and manufacture registered starting materials( RSMs) and intermediates within an integrated scientific environment provides important advantages. It supports improved supply chain control, reduces dependency on fragmented external networks and enables greater visibility of quality-critical parameters earlier in development.
Integration that starts earlier
Drug substance and drug product development are often managed as separate workstreams. However, decisions made at the API stage can have a direct impact on formulation performance, manufacturability, stability, analytical methods and ultimately patient usability.
By bringing these disciplines closer together, Almac helps clients consider the downstream implications of upstream decisions from the outset. This is particularly important for challenging molecules where solubility, stability, polymorphism, particle size, impurity profile or process robustness may influence the final dosage form.
An integrated model enables scientific teams to assess how the properties of the drug substance affect the drug product, and vice versa. This can support better control strategies, more efficient development planning and fewer latestage surprises.
Rather than viewing API development, formulation and clinical supply as separate milestones, an integrated approach treats them as connected elements of one programme. For clients, this
means clearer communication, stronger technical alignment and a more efficient path from molecule to medicine.
Addressing bioavailability challenges
Bioavailability remains one of the most common and important challenges in drug development. Many promising compounds present difficulties related to poor solubility, permeability, stability or manufacturability. If these challenges are not addressed early, they can lead to delays, reformulation, increased cost and clinical risk.
Almac’ s integrated expertise supports a more proactive approach to bioavailability enhancement. By combining drug substance knowledge with formulation and analytical capability, teams can evaluate key material attributes and formulation options in parallel.
For clients, this integration can be especially valuable when developing complex or poorly soluble molecules. It allows potential issues to be identified earlier, technical options to be assessed more efficiently and development strategies to be adapted with greater confidence.
66 SPECIALITY CHEMICALS MAGAZINE ESTABLISHED 1981